COYA Stock Forecast & Price Target

Coya Therapeutics is a clinical stage biotechnology company with a positive outlook. They have a promising product, COYA 302, which is currently in a Phase 2 trial for ALS. This product has shown both safety and efficacy in clinical and pre-clinical studies and has received Fast Track Designation from the FDA. Additionally, Coya's focus on harnessing regulatory T cells (Tregs) to target neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases sets them apart in a growing field of research.

Coya Therapeutics is a clinical-stage biotechnology company with a focus on developing therapies for neurodegenerative diseases. Despite having a well-funded balance sheet and a strong commercial partner, the company carries a high level of clinical risk due to its relatively small exploratory studies and concentration of value in its lead program. In addition, the company will likely need to raise additional funds in the future, which could be dilutive to shareholders. Our discounted cash flow analysis yields a 12-month price target of $12 per share, assuming a 50% probability of approval for COYA 302 in ALS and FTD indications, and we maintain a negative outlook due to the high level of clinical risk and potential dilution.